The invention provides active agents, such as paclitaxel, rapamycin, or 17-DMAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) ("PEG-b-PLA") micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-DMAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor TM EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PL...

The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients.

Pharmaceutical compositions useful for hydrophobic agents paclitaxel paclitaxel analogs and conjugates thereof (e g ANG1005) which do not contain Cremophor The compositions further comprise an optional tonicity agent a buffering agent a bulking agent and a solubilizmg agent which is not Cremophor Methods of preparing said compositions and of said compositions in the treatment of cancer are also included.

Anti-angiogenic gene therapy with a combination of soluble Vascular Endothelial Growth Factors (sVEGFR) improves the efficacy of chemotherapy with paclitaxel for reducing ovarian cancer mean tumor volume (in cubic millimetres) as measured using magnetic resonance imaging. The study groups were: AdLacZ control combination of AdsVEGFR-1 -2 and -3 combination of AdsVEGFR-1 -2 -3 and paclitaxel bevacizumab monotherapy paclitaxel monotherapy and carboplatin monotherapy. Effectiveness was assessed by ...

The present invention provides a method for treatment of cancer comprising administration of an arginine reducing compound and a chemotherapeutic/target therapeutic drug to a subject in need thereof. In one embodiment the cancer is liver cancer or prostate cancer. In another embodiment the arginine reducing compound is pegylated recombinant human arginase and the chemotherapeutic/target therapeutic drug is oxaliplatin everolimus paclitaxel or sorafenib.